摘要
目的:探讨硼替佐米(Bortezomib,BTZ)治疗老年多发性骨髓瘤(Multiple myeloma,MM)的效果及对骨代谢和尿溶酶体酶(N-aletyl-β-D-glucosaminidase,NAG)、β2-微球蛋白(β2-microglobulin,β2-MG)水平的影响。方法:选取2020年03月~2021年12月我院血液科收治的78例老年MM患者作为研究对象,按照随机数字表法分为对照组和观察组,各39例。对照组采用沙利度胺(Thalidomide,THD)治疗,观察组采用BTZ治疗。比较两组治疗疗效、骨髓功能、骨代谢指标以及肾功能与安全性。结果:观察组治疗总有效率明显大于对照组(P<0.05)。治疗后,观察组血红蛋白水平明显高于对照组(P<0.05),血清M蛋白及骨髓浆细胞水平、核因子KB受体活化因子配体、人抗酒石酸磷酸酶、NAG、胱抑素与β2-MG水平明显低于对照组(P<0.05)。观察组总不良反应发生率明显小于对照组(P<0.05)。结论:BTZ用于治疗老年MM效果良好,可有效改善患者骨髓功能,降低骨代谢水平,且对肾功能影响小,临床应用安全性相对较高。
Objective:To explore the effect of bortezomib(BTZ)in the treatment of elderly multiple myeloma(MM)and the influence on bone metabolism and levels of urinary lysosomal enzyme N-acetyl-β-D-glucosaminidase(NAG)andβ2-microglobulin(β2-MG).Methods:Seventy-eight elderly patients with MM who were treated in department of hematology of the hospital from March 2020 to December 2021 were selected as the study subjects and were divided into control group and observation group according to the random number table method,with 39 cases in each group.The control group received thalidomide(THD)treatment,and the observation group was given BTZ treatment.The therapeutic efficacy,bone marrow function,bone metabolism indicators,renal function and safety were compared between the two groups.Results:The total effective rate of treatment in observation group was significantly higher than that in control group(P<0.05).The hemoglobin level in observation group after treatment was significantly higher than that in control group(P<0.05)while the levels of serum M protein,bone marrow plasma cell,nuclear factor KB receptor activation factor ligand,human tartrate-resistant acid phosphatase,NAG,cystatin andβ2-MG were significantly lower than those in control group(P<0.05).The total incidence rate of adverse reactions was significantly lower in observation group than that in control group(P<0.05).Conclusion:BTZ has a good effect in the treatment of elderly MM,and it can effectively improve the bone marrow function and reduce the bone metabolism level,and it has small effect on renal function and has relatively high safety in clinical application.
作者
典雪珂
Dian Xue-ke(Department of Hematologic Lymphoma,The First People’s Hospital of Pingdingshan,Pingdingshan 467000,Henan,China)
出处
《四川生理科学杂志》
2024年第2期391-394,共4页
Sichuan Journal of Physiological Sciences
关键词
硼替佐米
老年多发性骨髓瘤
疗效
骨代谢指标
Bortezomib
Elderly multiple myeloma
Efficacy
Bone metabolism indicators
